| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Human umbilical cord blood (HUCB) cells are currently being used for autologous transplantation in the treatment of patients with cerebral palsy. However, it is unknown how HUCB cells, as a model of cell-based therapy, interact with brain parenchymal cells, and promote functional recovery. We hypothesized that HUBC cells communicate with parenchymal cells via exosomes. To investigate to the neuroprotective effects of HUCB cells derived-exosomes, we used the in vitro oxygen-glucose deprivation (OGD) model in SH-SY5Y cells. HUCB cells were exposed to the cerebral tissue extracts from mice subjected to hypoxic-ischemic encephalopathy (HIE). After 48hr culture, the exosome fractions were isolated and added to OGD SH-SY5Y cells culture. We found that HUCB cells derived-exosomes exposed HIE brain extracts significantly increased the viability of and attenuated the apoptosis of SH-SY5Y cells.
|
